MedAffairs Series -Online Conference
ARTIFICIAL INTELLIGENCE, DIAGNOSIS, AND IMAGING
5 Reasons to attend (online):
- Navigate the oncology stakeholder ecosystem & how medical affairs can add value
- Benchmark with leading experts on oncology KOL engagement, stakeholder communication, collaboration and insight generation
- Understand the capabilities required to achieve for medical affairs effectiveness in oncology
- Appreciate what do cancer stakeholders (patients, payers, cancer hospitals, physicians) specifically need?
- Learn how to develop advanced real-world and clinical evidence to develop high-value therapies
January 26-27, 2021
https://www.nextlevells.com/events/medaffairs-oncology-20
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE